Correction to “Increased Expression of miR‐641 Contributes to Erlotinib Resistance in Non‐Small‐Cell Lung Cancer Cells by Targeting NF1”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPeptidase Inhibition and Analysis · Lung Cancer Treatments and Mutations · Cancer Mechanisms and Therapy
Chen J, Cui J‐d, Guo X‐t, Cao X, Li Q. “Increased expression of miR‐641 contributes to erlotinib resistance in non‐small‐cell lung cancer cells by targeting NF 1.” Cancer Med. 2018; 7:1394–1403. https://doi.org/10.1002/cam4.1326.
In Figure 2D, an error occurred during the preparation of the figure, where incorrect representative flow cytometric plots were inadvertently selected. This has now been corrected and is shown below. The updated Figure 2D includes the correct representative plots, which accurately reflect the results of our experiment. Please refer to the revised figure for the accurate representation of the flow cytometric analysis. We would like to emphasize that this correction does not alter the conclusions of the study, as the error was limited to the selection of representative data and did not affect the interpretation or validity of the findings.
We apologize for this error.